Stay updated on Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the completed Phase II study of pembrolizumab with or without bevacizumab for recurrent glioblastoma is displayed, including its study design, outcomes, eligibility criteria, and locations.
    Difference
    56%
    Check dated 2026-11-09T13:20:14.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0, while the study record continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T12:53:38.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov study-record page continues to display a 403 Forbidden error. An NIH notice about terminology changes appears above the page, and the site revision number advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-26T15:50:10.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T15:44:07.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing access to the study record with an access-denied message. The header and footer remain visible, but the main content is inaccessible.
    Difference
    0.5%
    Check dated 2026-09-28T17:42:49.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The study page now loads a 403 Forbidden error, replacing the prior study content. Visually, the page shows a standard 403 wrapper with site chrome, and the detailed study information is no longer visible.
    Difference
    19%
    Check dated 2026-09-21T22:20:58.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.